Search

Displaying results 4441 - 4450 of 7063 in total
  1. Drug

    MGN-4893

    go.drugbank.com/drugs/DB17338
    Experimental

    In February 2011, it was granted FDA orphan designation for the treatment of polycythemia vera.[L47356]

  2. Drug

    Valiltramiprosate

    go.drugbank.com/drugs/DB19191
    Investigational

    Valiltramiprosate is under investigation in clinical trial NCT06304883 (Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects).

  3. Drug

    Anisomycin

    go.drugbank.com/drugs/DB07374
    Experimental

    This drug acts to inhibit bacterial protein and DNA synthesis.

  4. Drug

    Bermekimab

    go.drugbank.com/drugs/DB14947
    Investigational

    Bermekimab is under investigation in clinical trial NCT01384630 (Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis).

    Synonyms: RA-18C3
  5. Drug

    CH-1504 L-isomer

    go.drugbank.com/drugs/DB19052
    Investigational

    CH-1504 L-isomer is under investigation in clinical trial NCT01116141 (A Study of CH-4051 in Patients With Rheumatoid Arthritis (RA)).

  6. Drug

    Renadirsen

    go.drugbank.com/drugs/DB19132
    Investigational

    Renadirsen is under investigation in clinical trial NCT04433234 (Long-term, Extension Study of Ds-5141b in Patients With Duchenne Muscular Dystrophy).

  7. Drug

    TAS-102

    go.drugbank.com/drugs/DB08937
    Investigational

    Trifluridine inhibits tumor growth by being incorporated into DNA during DNA synthesis. Tipiracil prevents trifluridine from being broken down when taken orally.

  8. Drug

    Penpulimab

    go.drugbank.com/drugs/DB16747
    ApprovedInvestigational

    Penpulimab is a humanized monoclonal IgG1 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). … [A273843,A273848] Penpulimab-kcqx was approved by the US FDA in April 2025 for the treatment of nasopharyngeal carcinoma in select patients.[L52993,L52998]

  9. Drug

    Atacicept

    go.drugbank.com/drugs/DB06399
    ApprovedInvestigational

    factor (BAFF) and A Proliferation Inducing Ligand (APRIL). … Atacicept is a recombinant fusion glycoprotein that joins the ligand-binding portion of the human TACI receptor to a modified IgG1 Fc domain, allowing it to bind and neutralize two cytokines: B cell activating

  10. Drug

    Tirbanibulin

    go.drugbank.com/drugs/DB06137
    ApprovedInvestigational

    Tirbanibulin (KX-O1 or KX2–391) is a dual inhibitor of Src Kinase and tubulin. … [L27806] Actinic keratosis is a chronic condition characterized by lesions, which can potentially transform into invasive squamous cell carcinoma with a risk of 1% over 10 years.